1 / 11

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy.

kelton
Télécharger la présentation

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. Heise, Ph.D., William H. Herman, M.D., M.P.H., Rury R. Holman, F.R.C.P., Nigel P. Jones, M.A., Barbara G. Kravitz, M.S., John M. Lachin, Sc.D., M. Colleen O'Neill, B.Sc., Bernard Zinman, M.D., F.R.C.P.C., Giancarlo Viberti, M.D., F.R.C.P., for the ADOPT Study Group Study Overview • This double-blind, randomized, controlled trial evaluated rosiglitazone, metformin, and glyburide as an initial treatment in patients with type 2 diabetes • Rosiglitazone reduced the risk of treatment failure (the primary outcome) by 32% as compared with metformin and by 63% as compared with glyburide • The potential risks, benefits, and costs of these medications should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  2. Enrollment and Outcomes Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  3. Baseline Characteristics of the Patients* - Part I Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  4. Baseline Characteristics of the Patients* - Part II Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  5. Kaplan-Meier Estimates of the Cumulative Incidence of Monotherapy Failure at 5 Years Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  6. Hazard Ratio for Monotherapy Failure in the Rosiglitazone Group, as Compared with the Metformin and Glyburide Groups in Key Subgroups Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  7. Fasting Plasma Glucose (Panel A), Glycated Hemoglobin (Panel B), Insulin Sensitivity (Panel C), β-Cell Function (Panel D), over Time, According to Treatment Group Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  8. Weight (Panel E), Waist Circumference (Panel F), Hip Circumference (Panel G), and Waist-to-Hip Ratio (Panel H) over Time, According to Treatment Group Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  9. Adverse Events, Laboratory Assessment, Concomitant Use of Cardiovascular Drugs, Hospitalization, and Death* - Part I Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  10. Adverse Events, Laboratory Assessment, Concomitant Use of Cardiovascular Drugs, Hospitalization, and Death* - Part II Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

  11. Rate of Fractures Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355:2427-43

More Related